evipedia.ai
← Back

Ovagen for Health & Longevity

Evidence Review created on 09/22/2026 using AI4L / Opus 5

Also known as: EDL, Glu-Asp-Leu, Glutamyl-aspartyl-leucine

Motivation

Ovagen is a laboratory-made compound of three amino acids — glutamic acid, aspartic acid and leucine. It belongs to a family of very short amino acid compounds developed in Russia and sold for liver and digestive support. The idea behind the family is that molecules this small can enter cells and shift which genes are switched on.

The family grew out of Soviet military medicine in the 1970s, where researchers prepared organ extracts intended to speed recovery after radiation and stress, and was later reworked into short synthetic sequences, each assigned to a single organ. Ovagen carries the liver and digestive assignment. Capsules and injectable powders are now sold worldwide, largely outside formal drug regulation.

This review examines what the published record contains for Ovagen itself: where the compound has been tested, what those tests measured, what remains untested in people, how the reported risks are distributed, and how the protocols in circulation were arrived at. It separates evidence about Ovagen from evidence about the family it belongs to.

Benefits - Risks - Protocol - Conclusion

This section lists high-level sources on Ovagen — the tripeptide EDL (the one-letter code for its three amino acids), one of the synthetic “cytogens” (short laboratory-made sequences, each assigned to one organ) in the Russian bioregulator series — and on the peptide-therapeutics category it sits within.

Note on the priority platforms: no relevant content was found on foundmyfitness.com, chriskresser.com, lifeextension.com or lifespan.io. Ovagen is a niche unapproved compound with no human trial record, and none of these four has written about it; lifespan.io’s only cytogen-series item is a short news report on a single mouse egg-cell study of Epitalon, which is not a high-level overview of the compound or its category. Five sources are listed, and none was included merely to reach that count.

Grokipedia

  • Ovagen

    Structured overview of Ovagen’s sequence, origin in the Khavinson cytogen series, and the limits of its evidence, with the preclinical-only status stated plainly. Useful as an orientation before reading the primary papers.

Examine

No Examine article exists for Ovagen; a direct search of examine.com returned no results for the term. Ovagen is an unapproved synthetic peptide sold as a research compound, not a supplement ingredient within Examine’s coverage.

ConsumerLab

No ConsumerLab article, product review or test report exists for Ovagen; a direct search of consumerlab.com returned no results. ConsumerLab tests retail supplement products, and Ovagen is not sold through that retail channel.

Systematic Reviews

The single systematic review below is the only indexed evidence synthesis that mentions Ovagen’s tripeptide at all.

Ovagen involves a trade-off between an unproven benefit and a real supply-chain hazard. The benefit side is represented above, at one remove. The risk side is unrepresented: no systematic review or meta-analysis addresses the safety, contamination profile or adverse-event record of Ovagen or of the cytogen series, so the risk literature in this review rests on primary studies instead. The review listed is also authored by the group that patents and licenses these peptides, which is the only synthesis available on this side of the trade-off.

Mechanism of Action

Ovagen is the tripeptide glutamyl-aspartyl-leucine, written EDL after the one-letter codes for its three amino acids, with a molar mass of about 375 g/mol.

Its originators propose a three-step mechanism. Entry: di- and tripeptides cross cell membranes through the proton-coupled peptide transporters PEPT1 and PEPT2 and possibly through LAT carriers (large neutral amino acid transporters, which move amino acids in and out of cells); a 2022 review from the same institute maps this route for peptides of this size. Nuclear access: fluorescently labelled peptides of this family reach the nucleus and nucleolus of cultured human cells. Transcriptional effect: the same peptides bind histones — the protein spools that DNA (deoxyribonucleic acid, the cell’s genetic material) winds around — and defined DNA sequences, which is proposed to open or close particular gene promoters. The institute advancing this model licenses the commercial peptides built on it.

A competing reading fits the same data. Free tripeptides are hydrolysed by blood and brush-border peptidases within minutes; no receptor for EDL has been identified; no half-life or any other human pharmacokinetic value has been published for Ovagen. The culture effects may therefore reflect amino acid supply or assay conditions rather than sequence-specific gene regulation. Metabolism is peptidase-driven rather than cytochrome P450 (CYP, the liver’s main drug-metabolising enzyme system) dependent, and distribution follows transporter expression — intestine, kidney, lung, brain — not a liver-selective route.

Historical Context & Evolution

Ovagen’s line begins in Soviet military medicine. In the 1970s Vladimir Khavinson and Vyacheslav Morozov, at the Kirov Military Medical Academy, extracted low-molecular-weight peptide fractions from calf organs, called cytomedins, and reported that a fraction from one organ selectively stimulated tissue of that same organ. The original purpose was restoring immune and blood-forming function after radiation and operational stress, not longevity.

The longevity framing came with the clinical work. A 6–8 year follow-up of 266 older adults given the thymus and pineal extracts Thymalin and Epithalamin reported lower rates of respiratory illness, ischaemic heart disease and osteoporosis, and death rates 1.6 to 2.5 times lower than controls. That study was unblinded and single-centre, and it has not been reproduced elsewhere. Its authors’ institute, the St Petersburg Institute of Bioregulation and Gerontology, holds the patents and licenses the commercial preparations, so the organisation stating this position derives direct revenue from it.

A second generation of short synthetic sequences followed, each assigned an organ: Vilon for thymus, Epitalon for pineal, Livagen for liver, Bronchogen for lung, Pinealon for brain. Ovagen was assigned liver and digestive tract. Notably, the organ-culture work that established tissue selectivity named Livagen, not Ovagen, as the liver sequence. What has changed since runs both ways: transporter and molecular-modelling work has supplied a plausible entry route, while no laboratory outside this lineage has reproduced sequence-specific DNA binding at physiological concentrations.

Expected Benefits

For a reader already optimising sleep, training, alcohol intake and body composition, the question is what Ovagen adds on top of that baseline. On the published record every candidate benefit sits at the lowest evidence tier, and the tiers above it are empty.

High 🟩 🟩 🟩

No benefit reaches High. The class of evidence required — a human clinical endpoint or a validated clinical surrogate, shown in more than one trial — does not exist for Ovagen; not one human study of any design has been published.

Medium 🟩 🟩

No benefit reaches Medium either. That tier needs the same class of human outcome in a single trial or in consistent observational data, and neither a trial nor an observational cohort of Ovagen users exists.

Low 🟩

Speculative 🟨

Hepatic Function Support

The marketed rationale is restored gene expression in liver cells. No indexed study has measured liver enzymes, bile flow or liver fat with Ovagen; the basis is unindexed Russian rodent reports of hepatoprotection.

Gastrointestinal Mucosal Integrity

Vendors describe support of the gut lining’s barrier function. No published experiment has exposed intestinal tissue to Ovagen; the basis is mechanistic reasoning from PEPT1 expression in the gut plus user reports.

Reduced Cellular Senescence Markers and Increased Cell Renewal

In aged rat kidney cell cultures EDL raised proliferation and SIRT6 (a repair-linked protein) while lowering p16, p21 and p53 (proteins that halt division in damaged cells). No human outcome exists.

Renal Protection After Kidney Injury

In rat models of drug-induced and ischaemic kidney injury EDL limited urine protein loss and preserved filtration. The basis is animal work from the originating group only.

Whole-Organism Geroprotection

Extrapolated from the family’s animal lifespan work, none of which used Ovagen. No experiment has given Ovagen to any animal and measured survival or lifespan, and no person has received it.

Benefit-Modifying Factors

  • Peptide transporter genotype: variants in SLC15A1, the gene encoding PEPT1, change how efficiently the gut absorbs di- and tripeptides. Carriers of low-activity variants would absorb an oral course less well. No genotype has ever been tested with Ovagen.
  • Baseline liver biomarkers: a proactive user with liver enzymes already in the optimal range has no margin in which a benefit could appear. Any measurable change is more plausible where enzymes start elevated, which is untested either way.
  • Sex-based differences: none have been studied. Women have lower reference ranges for the liver enzymes used to judge response, and lower average lean mass affects peptide transporter capacity, so identical dosing is not identical exposure.
  • Pre-existing health conditions: inflammatory bowel disease raises PEPT1 expression in inflamed colon tissue, plausibly increasing uptake. Cholestasis (stalled bile flow), advanced fibrosis and chronic kidney disease all alter peptide handling. None has been measured with Ovagen.
  • Age-related considerations: effects were larger in aged cell cultures than young ones, the stated reason older adults are targeted. For a user at the older end of the range this stays an inference from rodent cells, not an observed human gradient.

Potential Risks & Side Effects

The hazards with actual human data attach to the supply channel and the route of administration rather than to the molecule. That ordering is itself the finding.

High 🟥 🟥 🟥

No risk reaches High. That tier requires a human clinical endpoint or documented adverse-event series shown in more than one trial, and Ovagen has neither a trial record nor a pharmacovigilance dataset in any country.

Medium 🟥 🟥

No risk reaches Medium either. That tier requires the same class of human outcome in a single trial or in consistent observational data on the compound, and no study has ever administered Ovagen to a person.

Low 🟥

Contaminated or Misidentified Product

Ovagen is bought from research-chemical vendors outside pharmaceutical quality systems. Systematic impurity profiling of falsified peptide preparations sold this way found wide purity variation plus inorganic arsenic and lead. Severity depends on the contaminant; the hazard is the channel, not the molecule.

Magnitude: Across the ten most frequently falsified injectable peptide products on one national market, active-ingredient purity ranged from 5% to 75% among the cysteine-containing peptides, one sample carried lead, and several carried inorganic arsenic at up to ten times the international toxicity limit for injected medicines.

Injection-Site Infection and Injury

This applies only to the subcutaneous route, which many users prefer to capsules. Surveillance of men self-injecting non-medical compounds records frequent local inflammation and a smaller fraction progressing to abscess. Ovagen itself is unstudied; the exposure is the injecting practice, and most events resolve locally.

Magnitude: Among 366 men injecting image- and performance-enhancing compounds, 42% had ever experienced redness, swelling and tenderness at an injection site, and 6.8% an abscess or open wound.

Speculative 🟨

Suppression of Cell-Cycle Brakes

EDL lowered p16, p21 and p53 in cultured cells. Those proteins restrain damaged cells from dividing, so sustained suppression is a theoretical proliferative concern. No tumour data exist for Ovagen in any species.

Hypersensitivity and Immune Reaction

Any injected synthetic peptide can provoke a local or systemic allergic reaction. No case has been published for Ovagen; the basis is the compound class and isolated reports for related injectable peptides.

Delayed Evaluation of Abnormal Liver Tests

Using Ovagen for persistently raised liver enzymes can postpone diagnosis of hepatitis, fatty liver disease or biliary obstruction. No study has quantified this; the basis is the marketed indication rather than any reported harm.

Risk-Modifying Factors

  • Peptide transporter genotype: SLC15A1 and SLC15A2 encode PEPT1 and PEPT2, which move short peptides into gut and kidney cells. High-activity variants raise internal exposure to both the compound and any co-transported impurity.
  • Baseline biomarker levels: a user starting with raised liver enzymes, bilirubin or a fibrosis score above the screening threshold carries most of the delayed-diagnosis risk. Normal baseline values largely remove it.
  • Sex-based differences: the injection-harm data come almost entirely from men, so the prevalence figures may not transfer to women. No sex difference in peptide tolerance has been reported, because none has been looked for.
  • Pre-existing health conditions: active malignancy, immunosuppression after transplant, and inflammatory bowel disease each intersect with the proliferative and absorption concerns. Decompensated cirrhosis (advanced liver failure) makes any delay in proper evaluation consequential rather than merely wasteful.
  • Age-related considerations: older users take more medicines at once, so transporter competition matters more, and declining kidney filtration slows clearance of peptides and of heavy-metal contaminants. Skin healing after injection is also slower at the older end.

Key Interactions & Contraindications

  • Beta-lactam antibiotics and other PEPT1 substrates (cefadroxil, cephalexin, valacyclovir, enalapril): caution. These drugs use the same intestinal transporter, so co-dosing can reduce absorption of either. Protocols separate the oral doses by at least two hours.
  • Acid-suppressing medicines (omeprazole, esomeprazole, famotidine, calcium carbonate antacids): caution. PEPT1 is driven by a proton gradient, so sustained acid suppression may lower peptide uptake. Dosing is placed at the opposite end of the day.
  • Dietary protein and peptide-rich meals: caution. Food-derived di- and tripeptides saturate the same carrier, reducing uptake. This is why standard protocols place every dose 20–30 minutes before food rather than with it.
  • Hepatotoxic agents (paracetamol above 3 g/day, high-dose niacin, kava, concentrated green tea catechin extracts): monitor. Each can raise liver enzymes independently, masking or mimicking a response and confounding the only measurable endpoint available.
  • Supplements acting on the same liver targets (silymarin from Silybum marianum, N-acetylcysteine, tauroursodeoxycholic acid): caution, additive on liver-enzyme endpoints. Concurrent use with Ovagen makes attribution impossible; protocols introduce one agent at a time.
  • Other organ bioregulator peptides (Epitalon, Pinealon, Livagen): caution. Stacking multiplies exposure to product-quality hazards without adding evidence. No interaction study exists for any pair in this series.
  • Immunosuppressants and cytotoxic chemotherapy (tacrolimus, ciclosporin, methotrexate): absolute contraindication during active treatment. A proliferation-promoting signal of unknown magnitude works directly against therapy designed to suppress proliferation.

Populations who should avoid Ovagen:

  • Anyone with active malignancy, or in remission less than 5 years
  • Solid-organ transplant recipients on maintenance immunosuppression
  • Pregnancy, lactation, and anyone under 18 years
  • Decompensated cirrhosis (Child-Pugh Class C, the most severe grade of liver failure) or acute hepatitis with alanine aminotransferase above 5 times the upper limit of normal
  • Advanced chronic kidney disease (estimated glomerular filtration rate below 30 mL/min/1.73 m²), since PEPT2 handles these peptides renally and clearance is unstudied
  • Known hypersensitivity to the preparation or its excipients

Risk Mitigation Strategies

  • Batch certificate of analysis before purchase: a batch report giving identity by mass spectrometry, purity at or above 98% by high-performance liquid chromatography, plus heavy-metal and endotoxin results. This is the direct control on the contaminated or misidentified product risk.
  • Oral route as the default: capsules remove the injection-site infection and injury risk entirely. Subcutaneous use is reserved for settings where a clinician supervises technique, sterile handling and disposal.
  • Liver panel before and 4 weeks after every course: alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase and bilirubin. This catches the delayed-evaluation risk and replaces impression with measurement.
  • Single-agent introduction: one 10–20 day course with nothing else changed, no other new supplement or peptide. Any adverse event then remains attributable, which concurrent use makes impossible.
  • Predefined stop rule: a pre-set threshold for discontinuation and evaluation — rash, wheeze, facial swelling, persistent abdominal pain, or an alanine aminotransferase rise above twice baseline. This limits both hypersensitivity and masked liver disease.
  • Exclusion during active cancer treatment or immunosuppression: avoidance for the duration of treatment, and for 5 years after cancer remission. This addresses the cell-cycle-brake suppression concern, which has no safety margin to work within.

Therapeutic Protocol

  • Standard oral course: the pattern published by the St Petersburg institute’s licensee is one to two 10 mg capsules twice daily before food, for 10 to 20 consecutive days, repeated two to three times per year.
  • Injectable alternative: clinicians working with this peptide series, among them Craig Koniver in the United States, use subcutaneous dosing in the region of 100–150 mcg daily for 10 to 20 days, reconstituted from freeze-dried powder.
  • Conventional alternative: hepatology practice for the same complaints uses no peptide at all. Weight reduction, alcohol elimination and treatment of the underlying metabolic or viral cause carry the outcome evidence these protocols lack.
  • Best time of day: morning, on an empty stomach, 20–30 minutes before the first meal, so that dietary peptides are not competing for the same intestinal carrier.
  • Expected half-life: none has been published for Ovagen. Tripeptides of this size disappear from plasma within minutes, which is the stated reason courses are given daily rather than as a depot preparation.
  • Single versus split dosing: protocols split the daily amount across two pre-meal doses rather than one. The stated rationale is avoiding transporter saturation, which has not been measured for this compound.
  • Genetic polymorphisms: no pharmacogenetic test is established. SLC15A1 variants affecting PEPT1 activity are the plausible candidate for differing absorption and are not used in practice.
  • Sex-based differences: no protocol in circulation distinguishes men from women, and no dosing study has examined sex as a variable. Identical capsule counts are given regardless.
  • Age-related considerations: courses are unchanged with age. The rodent-culture finding of larger effects in aged cells is the stated reason older adults are the target group, not a basis for a different dose.
  • Baseline biomarker levels: no protocol titrates dose against liver enzymes. A baseline panel is used to judge whether anything changed, not to set the starting amount.
  • Pre-existing health conditions: protocols offer no adjustment for kidney impairment, cholestasis or active gut inflammation, all of which alter peptide handling. Avoidance rather than dose reduction is the only documented response.

Discontinuation & Cycling

  • Course-based, not lifelong: every protocol in circulation is a fixed 10–20 day course rather than continuous use. Nothing in the literature supports indefinite dosing, and no long-term exposure data exist.
  • Withdrawal effects: none have been reported. A rapidly hydrolysed tripeptide with no identified receptor offers no plausible mechanism for dependence or rebound after stopping.
  • Tapering-off protocol: not applicable. Courses stop abruptly at day 10 to 20, and no source describes a taper, a step-down or any transition schedule.
  • Cycling for efficacy: two to three courses per year with 3–6 month gaps is the standard pattern. The stated rationale is avoiding transporter habituation, which has never been measured.
  • Stopping for cause: immediate discontinuation for rash, breathing difficulty, abdominal pain or a doubling of liver enzymes, with no restart until the cause has been identified.

Sourcing and Quality

  • Two distinct supply channels: capsules originate from the St Petersburg institute’s Russian licensee and reach other markets through resellers; freeze-dried powder comes from Western research-chemical vendors labelled “not for human consumption”. Quality expectations differ sharply between them.
  • What to look for: a batch-specific certificate of analysis showing identity by mass spectrometry, purity by high-performance liquid chromatography, and separate heavy-metal and bacterial endotoxin results. Vendors who supply only a generic purity claim are not verifiable.
  • Third-party testing: the meaningful report comes from an independent laboratory, not the seller’s own. A handful of vendors publish batch reports from outside testing houses; most publish none, which is the single clearest quality signal available.
  • Reputable channels: no compounding pharmacy in the United States can lawfully prepare Ovagen, since it is not a recognised bulk drug substance there. The Russian licensed capsule product is the only preparation made under a national supplement registration.
  • Formulation and storage: capsules are stable at room temperature. Freeze-dried powder is kept frozen or refrigerated and away from light; once reconstituted with bacteriostatic water it is refrigerated and used within a few weeks.

Practical Considerations

  • Time to effect: nothing establishes one. No study has measured any endpoint on any timescale, so the only anchor is the 10–20 day course length and the convention of repeat blood testing 4 weeks after it ends.
  • Common pitfalls: stacking several bioregulator peptides at once, buying without a certificate of analysis, dosing with meals instead of before them, and treating abnormal liver tests with a peptide instead of investigating their cause.
  • Regulatory status: Ovagen is not an approved prescription medicine anywhere, is not a lawful dietary ingredient in the United States, and is sold as a research chemical. In Russia it carries a national dietary supplement registration.
  • Cost and accessibility: a 20-capsule course or a 20 mg vial typically costs approximately 40 to 90 US dollars, so cost is not the barrier. Access is, since importation is the usual route and no payer covers it.

Interaction with Foundational Habits

  • Sleep: no direct interaction is reported or mechanistically expected, since Ovagen has no known activity in sleep-regulating tissue. Indirectly, users often combine it with Pinealon or Epitalon, which are promoted for sleep; concurrent use makes any sleep change unattributable, and separating them restores attribution.
  • Nutrition: direct and antagonistic. Dietary protein yields large quantities of di- and tripeptides that compete for the same PEPT1 carrier, so a dose taken with food is absorbed less. Protocols therefore place dosing 20–30 minutes before eating, and ordinary protein intake supplies these amino acids in far larger amounts.
  • Exercise: no interaction has been reported in either direction. Practically, intense or unaccustomed training raises alanine and aspartate aminotransferase from muscle turnover, which can be misread as a liver effect. A 48-hour gap before any blood draw removes that confounder.
  • Stress management: none directly. Indirectly, the parent research programme framed these peptides as recovery agents after operational stress, and chronic stress and alcohol both raise gamma-glutamyl transferase, which confounds the same panel used to judge a response.

Monitoring Protocol & Defining Success

Baseline testing precedes the first course and sets the reference against which any later change is read; without it a course yields impressions rather than data. A full liver panel, complete blood count, kidney function and an inflammation marker are drawn fasting on one morning, with transient elastography added where fatty liver is already suspected.

Ongoing monitoring follows a fixed cadence: the liver panel is repeated at the end of each 10–20 day course, again 4 weeks later, then every 6–12 months while courses continue. Kidney function and elastography repeat annually. Any value moving the wrong way is rechecked at 2 weeks before it is attributed.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Alanine aminotransferase (ALT) 10–26 U/L (men), 8–22 U/L (women) Most liver-specific enzyme; the primary response marker ALT is an enzyme released when liver cells are injured. Conventional labs flag only above 40–55 U/L, a much looser bar. Fasting, morning draw; intense exercise within 48 hours beforehand invalidates it.
Aspartate aminotransferase (AST) 10–26 U/L Pairs with ALT; a ratio above 1 points to alcohol or fibrosis AST is a related enzyme also present in muscle and heart. Conventional upper limit is about 40 U/L. Draw on the same sample as ALT.
Gamma-glutamyl transferase (GGT) Below 25 U/L (men), below 18 U/L (women) Sensitive to alcohol, bile flow and oxidative load GGT is a bile-duct enzyme. Conventional ranges extend to 60–70 U/L. It rises before ALT with alcohol, so it is the better early alcohol check.
Alkaline phosphatase (ALP) 60–90 U/L Detects bile obstruction, the main alternative explanation for liver symptoms ALP is an enzyme from bile ducts and bone. Conventional range is 40–130 U/L. Pair with GGT to separate a bone source from a bile source.
Total bilirubin 0.4–1.0 mg/dL Bile handling and red cell turnover An isolated rise with normal enzymes usually means Gilbert syndrome, a harmless inherited variation in bilirubin processing. Fasting and dehydration both raise it.
Albumin 4.2–5.0 g/dL Synthetic liver function; falls only with genuine impairment Conventional range is 3.5–5.0 g/dL. It also falls with inflammation, so read it beside the inflammation marker rather than alone.
Platelet count 200–350 ×10⁹/L A falling count is the earliest routine sign of portal hypertension Portal hypertension is raised pressure in the vein feeding the liver. Conventional range is 150–400 ×10⁹/L. Comes with the complete blood count; no fasting needed.
Fibrosis-4 index (FIB-4) Below 1.30 Calculated fibrosis screen; decides whether imaging is warranted FIB-4 is computed from age, ALT, AST and platelet count, so it needs no extra blood. 1.30–2.67 is indeterminate; above 2.67 warrants specialist assessment.
High-sensitivity C-reactive protein (hs-CRP) Below 1.0 mg/L Background inflammation that confounds liver enzyme readings hs-CRP is a general marker of inflammation measured at low concentrations. The conventional cut-off is 3.0 mg/L. Invalid within 2 weeks of infection or unusually hard training.
Estimated glomerular filtration rate (eGFR) Above 90 mL/min/1.73 m² Ovagen’s only published cell data are renal, and its clearance is unstudied eGFR is a calculated measure of how fast the kidneys filter blood. The conventional threshold is 60. The creatinine it is derived from rises with muscle mass and creatine use.
Liver stiffness by transient elastography Below 6.0 kPa Direct fibrosis measure; the hard endpoint any liver claim must move Transient elastography is an ultrasound scan of liver stiffness. Its fat reading above 260 dB/m indicates steatosis (fat build-up inside the liver). Requires 3 hours fasting; annual at most.
Ovagen-specific response marker No established target exists; track the change from the individual’s own pre-course values across the panel above No validated biomarker of Ovagen activity has been defined No study has identified a marker that responds to this compound, so there is nothing to aim at. Only within-person change across courses is interpretable.

Qualitative markers:

  • Digestive comfort: bloating, fullness, stool regularity
  • Energy and clarity: morning energy, afternoon slump, rated 1 to 10
  • Sleep: total time and awakenings
  • Skin and appetite: itching, yellowing or appetite loss, all warning signs

Emerging Research

  • No registered trial of Ovagen: a September 2026 search of ClinicalTrials.gov returns no study of Ovagen or EDL in any phase or status. The compound’s entire record stays preclinical, so nothing currently running can confirm or refute the marketed liver and digestive claims.
  • Geroscience platform trials as the realistic test bed: PROMETHEUS (NCT07451496), recruiting 20 adults aged 50–80 in Singapore, pairs personalised supplementation with epigenetic-clock and liver-panel readouts. It does not include Ovagen, but it is the design a compound like it would have to enter.
  • The endpoint set any liver claim must clear: a randomised comparison in fatty liver disease with liver enlargement (NCT07068191), 90 participants across three arms, tests a supplement against ursodeoxycholic acid and ademetionine on a 30% alanine aminotransferase reduction at 15 days.
  • Independent replication of the peptide-DNA mechanism: would strengthen the case. The binding work of Fedoreyeva et al., 2013 has not been repeated outside the collaborating groups; a replication at physiological concentrations by an unaffiliated laboratory is the decisive missing experiment.
  • Measured oral bioavailability: could weaken the case sharply. Brandsch et al., 2008 catalogued which di- and tripeptides PEPT1 accepts; showing that EDL is either not transported intact or is hydrolysed before absorption would undercut every oral protocol.
  • Wider product-quality surveillance: would sharpen the risk estimate in either direction. Janvier et al., 2018 profiled falsified injectable peptides on one national market; equivalent sampling of bioregulator capsules would show whether that contamination pattern extends to this channel.

Conclusion

Ovagen is a three-amino-acid compound sold as the liver and digestive member of a Russian family of very short amino acid products. For someone already managing sleep, training, alcohol and body composition, the published record offers almost nothing to add to that work. No study has given Ovagen to a person. Its biological results in the international literature are in cells and animals, and both were kidney rather than liver; the liver assignment rests on Russian reports and product literature outside it. Every listed benefit therefore sits at the lowest level of confidence.

The documented risks are equally indirect, and they attach to how the product is obtained rather than to the compound. Preparations of this kind, bought outside pharmaceutical quality systems, have been found to vary widely in content and to carry toxic metals, and injecting rather than taking it orally adds skin infection and injury. The concern about pushing cells to divide remains untested in any animal.

The evidence base is narrow in a way that matters. Almost all of it comes from a single institute, which holds the patents and licenses the commercial product, while the sellers and clinics promoting it also profit from its use. With no owner of a patentable asset on either side, the human record has stayed empty rather than turning negative, and the uncertainty here is close to total.

Top - Benefits - Risks - Protocol